LENZ - LENZ Therapeutics, Inc. News

HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $16

HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a

seekingalpha.com

LENZ Therapeutics, Inc. (LENZ) Q3 2026 Earnings Call Transcript

LENZ Therapeutics, Inc. ( LENZ ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Particip

marketbeat.com

LENZ Therapeutics Q3 Earnings Call Highlights

LENZ Therapeutics NASDAQ: LENZ reported third-quarter 2026 product revenue of $2.6 million, up 50% s

TD Cowen Maintains Buy on LENZ Therapeutics, Lowers Price Target to $45

TD Cowen analyst Stacy Ku maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the pri

LENZ Therapeutics Q3 2026 Earnings Call Transcript

LENZ Therapeutics (NASDAQ:LENZ) reported third-quarter financial results on Thursday. The transcript

zacks.com

LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $0.99 per share versus the Zacks Co

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 20.4% to $0.34 during Wednesday's after-market

LENZ Therapeutics Appoints CFO Dan Chevallard As Interim President, CEO, Effective Dec. 1, Succeedin

LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or the "Company"), a pharmaceutical

LENZ Therapeutics Q3 EPS $(0.99) Misses $(0.98) Estimate, Sales $3.384M Miss $4.200M Estimate

LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.99) per share which missed the anal

LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketi

Q3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q

LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the

TD Cowen Maintains Buy on LENZ Therapeutics, Lowers Price Target to $50

TD Cowen analyst Stacy Ku maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the pri

Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $5

Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and low

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics,

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics,

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics,

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics,

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics,

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

defenseworld.net

Head to Head Comparison: Eloxx Pharmaceuticals (NASDAQ:ELOX) & LENZ Therapeutics (NASDAQ:LENZ)

LENZ Therapeutics (NASDAQ: LENZ - Get Free Report) and Eloxx Pharmaceuticals (NASDAQ: ELOX - Get Fre

marketwatch.com

These beaten-down stocks could bounce back in January, if history is any guide

Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth qu

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics,

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics,

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics,

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics,

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

seekingalpha.com

LENZ Therapeutics: Still Speculative But Priced For Disasters

LENZ Therapeutics is rated a 'Strong Buy' with a fair value estimate of $21.3, reflecting ~266% upsi

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics,

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics,

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

defenseworld.net

Bank of America Corp DE Boosts Stock Position in LENZ Therapeutics, Inc. $LENZ

Bank of America Corp DE lifted its stake in LENZ Therapeutics, Inc. (NASDAQ: LENZ) by 377.4% in the

Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7

Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and low

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday&#39

LENZ Therapeutics Q2 EPS $(1.02) Beats $(1.06) Estimate, Sales $5.486M Beat $2.373M Estimate

LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.02) per share which beat the analys

HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ:LENZ) with

LENZ Therapeutics Announces Availability Of VIZZ Through Telehealth Platform

LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of

LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst

LENZ Therapeutics partners with Arrotex to commercialize VIZZ in Australia and New Zealand as analys

LENZ Therapeutics And Arrotex Pharma Announce Exclusive License And Commercialization Agreement For

LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Arrotex Pharmaceuticals Pty Ltd. ("Arrotex") today

Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $20

Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowe

HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $38

HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a

Piper Sandler Downgrades LENZ Therapeutics to Neutral, Lowers Price Target to $12

Piper Sandler analyst Biren Amin downgrades LENZ Therapeutics (NASDAQ:LENZ) from Overweight to Ne

LENZ Therapeutics Q1 EPS $(1.32) Misses $(1.05) Estimate, Sales $1.901M Beat $1.759M Estimate

LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.32) per share which missed the anal

Earnings Scheduled For May 11, 2026

HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $48

HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a

LENZ Therapeutics Files Marketing Authorization Application Review, Approval Of VIZZ To Medicines An

LENZ Therapeutics, Inc. (NASDAQ:LENZ) today announced that it has submitted a Marketing Authorizatio

Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $26

Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowe

B of A Securities Maintains Buy on LENZ Therapeutics, Lowers Price Target to $29

B of A Securities analyst Jason Gerberry maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and

LENZ Therapeutics Q4 EPS $(1.16) Misses $(0.96) Estimate, Sales $1.588M Miss $1.886M Estimate

LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.16) per share which missed the anal

Earnings Scheduled For March 24, 2026

Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings

LENZ Therapeutics (NASDAQ:LENZ) to release Q4 earnings on 3/24. Analysts expect loss of 90 cents/sha

LENZ Therapeutics Submits Marketing Authorization Application To EMA For Review, Approval Of VIZZ To

LENZ Therapeutics, Inc. (Nasdaq: LENZ) today announced that it has submitted a Marketing Authorizati

New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug

FDA approved Tenpoint's Yuvezzi eye drop for presbyopia, adding competition for LENZ's VIZZ